Xilio jumps after collaboration with AbbVie to develop cancer treatments

Xilio Therapeutics

12/02/2025 13:17

** Shares of drug developer Xilio Therapeutics  XLO.O  more
than double to $1.37 premarket
    ** AbbVie  ABBV.N  and XLO enters into collaboration and
option agreement to develop cancer immunotherapies
    ** Under terms of the deal, XLO to receive $52 million in an
upfront payment and will be eligible to receive up to about $2.1
billion in milestone payments
    ** Deal gives ABBV access to XLO's proprietary
tumor-activation technology to develop new immunotherapies
    ** In the last 12 months, XLO has fallen 7%

 (Reporting by Siddhi Mahatole)
 ((Siddhiprabhanjan.mahatole@thomsonreuters.com))